CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Leukemic and Lymphomatous Optic Neuropathy: A Case Series.
Leukemic and Lymphomatous Optic Neuropathy: A Case Series.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
白血病性和淋巴瘤性视神经病变诊断和治疗困难,目前文献中尚无诊断或治疗的金标准。我们帮助阐明应以多学科方式和个体化方式处理该病,以正确诊断和治疗视力丧失,同时根据患者的全身性疾病考虑其长期预后。
白血病和淋巴瘤背景下的视神经病变引起对中枢神经系统受累或复发的担忧,需要及时评估和治疗。迄今为止,白血病性视神经病变的诊断和管理金标准尚未建立。
病例系列及文献综述。选择两例具有代表性的病例,讨论其治疗过程及结果。
我们报告了7例白血病或淋巴瘤患者出现视神经浸润的病例。所有患者因推测为浸润性视神经病变而接受了类固醇治疗,其中4例患者接受了放射治疗。除1例外,所有患者在接受全身化疗的同时还接受了鞘内化疗。3例患者接受了CAR-T 细胞治疗。
Optic neuropathy in the context of leukemia and lymphoma raises concern for central nervous system involvement or relapse and warrants prompt evaluation and treatment. To date, a gold standard for the diagnosis and management of leukemic optic neuropathy has yet to be established.
Case series and review of the literature. Two illustrative cases were selected to discuss their treatment course and outcome.
We report 7 cases of patients with leukemia or lymphoma presenting with optic nerve infiltration. All patients received steroid therapy for presumed infiltrative optic neuropathy, and 4 patients underwent radiation therapy. Along with systemic chemotherapy, all patients received intrathecal chemotherapy except one. Three patients received chimeric antigen receptor T-cell therapy.
Leukemic and lymphomatous optic neuropathy is difficult to diagnose and treat, and there is no gold standard for diagnosis or treatment in the current literature. We help clarify how this disease should be approached in a multidisciplinary fashion and on an individual basis to correctly diagnose and treat the vision loss, while considering the patient's long-term prognosis based on their systemic disease.
MEMBER ACCOUNT
登录成功会直接打开下一页。